[Longevity Dispatch] 🧬 mRNA vs. MS · 🔬 The Gene That Delays Disease by 13 Years · 🍓 Fisetin: The Strawberry Senolytic Finally Tested in Humans + Longevity Recipe
News from the longevity, biohacking, health, and supplement fronts.
By Valérie Orsoni — Biohacker & Longevity Expert
Valérie Orsoni is a biohacker, author of 56 books, and founder of biohacker.fr. She has been tracking her biology through N=1 self-experimentation protocols since 1998. She is currently enrolled in Stanford Medicine’s longevity research certification program.
Week of July 5th, 2026 — ValBiohacker.com
🧬 mRNA Against Multiple Sclerosis: The Real Science Behind the Viral “71% Remission” Claim
You may have seen this image floating around: an Australian researcher, an mRNA therapy, and a shocking number — 71% complete remission in MS patients. Except that number doesn’t appear in any published study.
I checked. No clinical trial, no peer-reviewed publication mentions that percentage. It’s viral content manufactured for social media — but the real story behind it is actually more interesting than the fake one.
What’s Actually Happening
There are two serious mRNA approaches currently in development for MS, and neither does what the image claims.
Approach 1 — Targeting the virus, not myelin directly. Moderna is developing mRNA-1195, currently in Phase 2 trials. Contrary to what the infographic suggests, this therapy doesn’t “reprogram” immunity against myelin — it aims to prevent reactivation of the Epstein-Barr virus (EBV), now identified as a major triggering factor in MS. The logic: neutralize the dormant virus, and you may reduce disease activity upstream.
Approach 2 — Antigen-specific tolerance. An approach closer to what the image describes does exist in preclinical research: mRNA platforms encoding myelin proteins, designed to “re-educate” immune cells to tolerate myelin instead of attacking it. Results in animal models of autoimmune encephalomyelitis are promising — but no human clinical trial has been published on this specific approach yet.
⚠️ The nuance that matters: we’re talking about ongoing Phase 2 trials and preclinical research here — not a validated treatment. The gap between “encouraging results in mice” and “71% remission in humans” is enormous, and that’s exactly the kind of gap viral infographics love to erase. If MS affects you or someone you love, be wary of unsourced miracle claims — and stick to primary sources (ClinicalTrials.gov, Moderna, peer-reviewed publications).
My N=1
I don’t have MS, so there’s no personal protocol to share here — but this topic is a good reminder of why I fact-check every shocking number before passing it along. My rule of thumb: whenever a percentage looks too clean (71%, 95%, “complete cure”), I go find the source study. Nine times out of ten, it doesn’t exist as presented.
📌 Sources: ClinicalTrials.gov, NCT06735248 (mRNA-1195, Moderna, Phase 2); Nature Reviews Bioengineering, 2026.
🔬 The cGAS-STING Gene: Why Some Families Avoid Chronic Disease for 13 Extra Years
What if some families’ longevity isn’t luck — but a single genetic switch we’re only now starting to understand?
Presented June 16, 2026 at the European Society of Human Genetics conference in Gothenburg, a study from the Leiden Longevity Study (Netherlands) just identified what may be one of the strongest mechanisms ever found behind familial longevity.
What’s Behind It
Researchers analyzed the genomes of 212 “long-lived” families — sibships of nonagenarians sharing both parents. Comparing their genetic profiles to control groups, they identified 4 genomic regions enriched for longevity-related genes, narrowing the search field from 20,000 to 350 candidate genes.
The result: 12 rare genetic variants associated with better long-term health. The most striking one affects the cGAS gene (cyclic GMP-AMP synthase), a protein that normally triggers an inflammatory response when it detects DNA “out of place” in the cell — an antiviral alarm signal that becomes hyperactive with age and fuels inflammaging, the chronic low-grade inflammation that accelerates aging across nearly every system in the body.
The identified variant makes the cGAS protein less stable, and therefore less reactive — dampening activation of the downstream STING pathway without weakening overall immune defenses. The real-world result for carriers: onset of cardiometabolic disease (type 2 diabetes, hypertension, cardiovascular issues) delayed by roughly 13 years compared to controls, even with comparable lifestyles.
⚠️ The caveat to keep in mind: this variant is rare and was only identified in two families in the study — we’re far from a generalizable “miracle gene” for the broader population. These results were also presented at a conference; full peer-reviewed publication and replication in other cohorts are still pending. And carrying this variant doesn’t excuse anything — lifestyle remains the most actionable lever for the vast majority of us who don’t have it.
My N=1
I obviously can’t edit my genome — but the cGAS-STING pathway can be influenced by lifestyle, particularly by reducing oxidative stress and circulating damaged mitochondrial DNA (one of cGAS’s natural triggers). My protocol: 16:8 intermittent fasting five days a week, zone 2 training four times a week (to limit cellular debris accumulation), and tracking my heart rate variability on my Oura Ring as an indirect proxy for systemic inflammation. It’s not hard science on cGAS specifically, but it’s consistent with everything we know about reducing inflammaging.
📌 Sources: Annual Conference of the European Society of Human Genetics, Gothenburg, June 16, 2026; ScienceDaily, June 21, 2026; Leiden University Medical Center (Prof. Eline Slagboom, P. Putter).
🍓 Fisetin: The Strawberry Senolytic Finally Tested in Humans
What if the most promising compound for clearing your “zombie cells” wasn’t a chemo drug — but something already sitting in your fruit bowl?
We’ve covered the Dasatinib + Quercetin senolytic duo before. Fisetin plays in the same league — but with a much gentler profile, and it just crossed the threshold into serious human clinical trials.
The Mechanism
Fisetin is a natural flavonoid found in strawberries (its richest source), apples, grapes, and onions. Like synthetic senolytics, it works by disabling the anti-apoptotic survival pathways that let senescent cells — those “zombie cells” that stop dividing but keep secreting a toxic inflammatory cocktail (the well-known SASP) — persist in tissue.
A 2025 University of Colorado Boulder study compared fisetin’s effectiveness against two reference senolytic approaches: targeted genetic clearance of senescent cells (GCV) and the synthetic drug ABT-263. The verdict: no statistically significant difference between all three approaches in reducing frailty and improving grip strength (a recognized longevity biomarker) in aged mice.
On the human side, clinical translation is finally accelerating — there are now 32 active clinical trials on ClinicalTrials.gov specifically targeting fisetin, several published in 2025-2026, covering vascular function in older adults, physical recovery in breast cancer survivors, and frailty in multimorbid adults aged 70 to 90.
⚠️ The catch you need to know: fisetin suffers from very low bioavailability and rapid metabolism — the effective dose used in trials (roughly 20 mg/kg/day for 2 consecutive days) is far higher than what you can get from diet alone. Human trials are still few and small; we don’t yet have solid long-term efficacy data, nor a clear answer on optimal dosing for chronic versus intermittent supplementation.
My N=1
I do intermittent fisetin cycles — two consecutive days per month at a high dose, rather than daily intake, following the “hit-and-run” logic used in senolytic trial protocols (the idea being to clear senescent cells, then let the body regenerate, rather than maintaining constant exposure). I pair this with year-round consumption of organic strawberries — not for the therapeutic dose, but for the background effect. My tracking marker: my Oura HRV recovery in the days following each cycle, which is consistently improved.
📌 Sources: Murray et al., 2025, University of Colorado Boulder; ClinicalTrials.gov (NCT06133634, NCT06431932, TROFFi study); Geroscience, Dec. 2025.
🍓 Longevity Recipe: Anti-Inflammaging Strawberry-Pomegranate-Turmeric Bowl
A recipe designed to flood your body with compounds that act directly on the pathways covered in this issue: fisetin (senolytic), ellagic acid (anti-SASP), curcumin (NF-κB / cGAS-STING pathway).
Why this recipe? Strawberries are the most concentrated dietary source of fisetin — this issue’s featured senolytic. Pomegranate delivers ellagic acid, a precursor to urolithin A and a suppressor of the inflammatory SASP. Turmeric acts on the NF-κB pathway in synergy with the cGAS-STING modulation documented in the Leiden study. Black pepper (piperine) boosts curcumin bioavailability by up to 20-fold.
Ingredients (serves 2): → 10 oz fresh strawberries, hulled and halved → Seeds from ½ pomegranate (or ⅓ cup pure, unsweetened pomegranate juice) → 1 tsp turmeric powder → 1 pinch freshly ground black pepper → 1 tbsp extra-virgin olive oil (to solubilize the fat-soluble curcumin) → 1 tsp manuka honey (optional — anti-inflammatory properties) → A few fresh mint leaves → 1 oz walnuts (omega-3s, anti-inflammaging effect)
Instructions:
Arrange the strawberries and pomegranate seeds in a bowl.
In a small bowl, combine olive oil, turmeric, black pepper, and honey. Whisk into a smooth dressing.
Pour the dressing over the fruit and gently toss.
Top with crushed walnuts and fresh mint leaves.
Eat immediately — fisetin and curcumin oxidize quickly once mixed.
My N=1 tip: I make this bowl on the mornings following my monthly fisetin supplementation cycles — the idea being to add a dietary reinforcement layer during the “clearance” phase. And honestly, it’s also just delicious after a mountain hike.
Let’s keep going! Forza!
Valérie Orsoni
Biohacker since 1998 | Longevity Expert
Instagram : Valerie Orsoni
My fave brands + super promo codes here ==> ValerieOrsoni.com
My made-in-the-usa, clean, no fillers supplement line ==> ZellNova
🎙 Life Summit— Berlin (29-30 mai 2026)
🎙 Corsica Biohacking — Corsica (6-13 juin 2026)
🎙 Biohackers World Conference — New York (juin 2026)
🎙 RAADFest— Sedona (4-6 septembre 2026)
🎙 HealthSpan Summit — Los Angeles (2–4 oct. 2026)
🎙 Reclaiming Health & Longevity Symposium — El Salvador (8–9 nov. 2026)